Tumor metabolism as a factor affecting diversity in cancer cachexia
American Journal of Physiology-Cell Physiology · 2025
DOI: 10.1152/ajpcell.00677.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2025. Verfasst von Oliver F Bathe. Beteiligte Einrichtung: Department of Surgery and Oncology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Cachexia, Neoplasms, Energy Metabolism. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U of C | Cumming School of Medicine, University of Calgary (CSM).
Abstract (Originalsprache)
Cancer cachexia is a multifaceted metabolic syndrome characterized by muscle wasting, fat redistribution, and metabolic dysregulation, commonly associated with advanced cancer but sometimes also evident in early-stage disease. More subtle body composition changes have also been reported in association with cancer, including sarcopenia, myosteatosis, and increased fat radiodensity. Emerging evidence reveals that body composition changes including sarcopenia, myosteatosis, and increased fat radiodensity, arise from distinct biological mechanisms and significantly impact survival outcomes. Importantly, these features often occur independently, with their combined presence exacerbating poor prognoses. Tumor plays a pivotal role in driving these host changes, either by acting as a metabolic parasite or by releasing mediators that disrupt normal tissue function. This review explores the diversity of tumor metabolism. It highlights the potential for tumor-specific metabolic phenotypes to influence systemic effects, including fat redistribution and sarcopenia. Addressing this tumor-host metabolic interplay requires personalized approaches that disrupt tumor metabolism while preserving host health. Promising strategies include targeted pharmacological interventions and anticachexia agents like growth differentiation factor 15 (GDF-15) inhibitors. Nutritional modifications such as ketogenic diets and omega-3 fatty acid supplementation also merit further investigation. In addition to preserving muscle, these therapies will need to be evaluated for their capability to improve survival and quality of life. This review underscores the need for further research into tumor-driven metabolic effects on the host and the development of integrative treatment strategies to address the interconnected challenges of cancer progression and cachexia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery and Oncology, University of Calgary, Calgary, Alberta, Canada.
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Oliver F Bathe
Förderung
- U of C | Cumming School of Medicine, University of Calgary (CSM)
Zitieren
APA
Bathe, O. F. (2025). Tumor metabolism as a factor affecting diversity in cancer cachexia. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00677.2024
Vancouver
Bathe OF. Tumor metabolism as a factor affecting diversity in cancer cachexia. American Journal of Physiology-Cell Physiology. 2025. doi:10.1152/ajpcell.00677.2024
BibTeX
@article{Bathe2025,
author = {Bathe, Oliver F},
title = {Tumor metabolism as a factor affecting diversity in cancer cachexia},
journal = {American Journal of Physiology-Cell Physiology},
year = {2025},
doi = {10.1152/ajpcell.00677.2024}
}
EUVIMED